The Ohio State University Corporate Engagement Office

Back to All Technologies

Trimodal Chemoprevention via Controlled Release Polymeric Implants

Life Sciences
Drug Delivery
Therapeutics
College
College of Dentistry
Researchers
Mallery, Susan
Schwendeman, Steven
Licensing Manager
Paschall, Christopher
614/688-2727
paschall.12@osu.edu

TS-037740 — Biodegradable polymeric implants for local delivery of therapeutic agents to cancer sites as an alternative to traditional radiation or chemotherapy treatments.

While surgery remains the gold standard of primary treatment for solid tumors, such as oral squamous cell carcinoma (OSCC), adjunct therapies (i.e. radiation or chemotherapy) are commonly used for patients with advanced stage or non-resectable/recurrent cancers. However, both radiation and traditi…

The Need

While surgery remains the gold standard of primary treatment for solid tumors, such as oral squamous cell carcinoma (OSCC), adjunct therapies (i.e. radiation or chemotherapy) are commonly used for patients with advanced stage or non-resectable/recurrent cancers. However, both radiation and traditional chemotherapy elicit significant toxic systemic side effects. In contrast, local delivery formulations provide treatment-appropriate drug levels at the target site while avoiding systemic side effects.

The Technology

Researchers at The Ohio State University, led by Dr. Susan Mallery, developed locally injectable pharmaceuticals comprising of biodegradable polymer formulations combined with therapeutic agents that can be used to provide a controlled release of therapeutically-relevant levels of cancer preventing agents directly to the treatment site. The polymeric carrier, a forming gel or millicylinder implants, is determined by the desired length of drug release. In addition, an anti-interleukin 6 agent and a therapeutic agent selected from a synthetic vitamin A analogue or metabolite, an estradiol metabolite, or a combination thereof is included for treatment. The initial focus of the invention was for OSCC, but the therapeutic could potentially be applied in other tissue or organ based cancers, such as those originating from the breast or prostate.

Commercial Applications

  • Primary chemoprevention to inhibit progression of a precancerous lesion
  • Secondary chemoprevention to prevent recurrence of cancer
    • Breast cancer
    • Prostate cancer
    • Oral Cell Squamous Cell carcinoma

Benefits/Advantages

  • Minimizes toxic systemic side effects from intravenous cancer drug delivery
  • Biodegradable, controlled-release system for drug delivery
  • Localized treatment for cancers that may be inoperable or advanced stage